CARC-101C / Carcell Biopharma - LARVOL DELTA

First-in-Human Evaluation of CARC-101C, an Engineered Red Blood Cell Therapy Delivering an Insulin Autoantigen, in Adults with Autoimmune Type 1 Diabetes (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • First-in-human • P1 data • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

The Safety and Efficiency of a Single Dose of CARC-101C in Patients With Autoimmune Type 1 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

New P1 trial • Diabetes • Immunology • Metabolic Disorders • Type 1 Diabetes Mellitus